Eversept Partners LP Trims Position in Vaxcyte, Inc. $PCVX

Eversept Partners LP trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 15.8% during the fourth quarter, HoldingsChannel reports. The firm owned 1,197,722 shares of the company’s stock after selling 224,261 shares during the quarter. Vaxcyte comprises 2.8% of Eversept Partners LP’s portfolio, making the stock its 8th largest holding. Eversept Partners LP’s holdings in Vaxcyte were worth $55,263,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PCVX. Royal Bank of Canada boosted its position in shares of Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after purchasing an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Vaxcyte during the first quarter worth $219,000. Caxton Associates LLP bought a new stake in Vaxcyte in the 1st quarter valued at $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in Vaxcyte by 13.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after acquiring an additional 932 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Up 2.8%

PCVX opened at $50.67 on Thursday. The stock has a market capitalization of $7.32 billion, a P/E ratio of -7.36 and a beta of 1.24. Vaxcyte, Inc. has a 12 month low of $29.08 and a 12 month high of $65.00. The firm’s fifty day simple moving average is $53.74 and its 200 day simple moving average is $52.69.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the company earned ($1.04) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.

Insider Activity

In other Vaxcyte news, CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the sale, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at $1,738,500. The trade was a 9.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,500 shares of company stock worth $419,288 over the last three months. Insiders own 3.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on PCVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, BTIG Research boosted their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.